MiRNA在自身免疫性心肌炎中的研究进展  

Research progress of miRNA in autoimmune myocarditis

作　　者：周妤婕 陈治奎 ZHOU Yujie;CHEN Zhikui(Department of Cardiovascular Medicine,the Affiliated Lihuili Hospital,Ningbo University,Ningbo 315040,China)

机构地区：[1]宁波大学附属李惠利医院心血管内科,宁波315040

出　　处：《生命的化学》2023年第10期1562-1568,共7页Chemistry of Life

基　　金：宁波市自然科学基金项目(202003N4227)。

摘　　要：自身免疫性心肌炎(autoimmune myocarditis,AMC)常因机体的细胞和体液免疫功能障碍,引发心肌组织周围炎症细胞浸润,诱发自身免疫反应,进而逐渐发展为慢性损伤和扩张性心肌病,严重影响患者的预后。微小核糖核酸(microRNA,miRNA)常在自身免疫性心肌炎中表达失调,调控基因表达或免疫细胞激活与分化,参与调节心肌细胞的生长和凋亡。本文分别从miRNA在自身免疫性心肌炎中的潜在作用机制、诊断及预后的生物标志物及治疗方面,对miRNA在自身免疫性心肌炎中的研究进展及存在的问题进行简要阐述。Autoimmune myocarditis(AMC)is often caused by cellular and humoral immune dysfunction in the body,leading to infiltration of inflammatory cells around myocardial tissue,triggering an autoimmune response,and gradually developing into chronic injury and dilated cardiomyopathy,seriously affecting the prognosis of patients.MicroRNA(miRNA)is often dysregulated in autoimmune myocarditis,regulating gene expression or immune cell activation and differentiation,and participating in regulating the growth and apoptosis of myocardial cells.This review briefly elaborates on the research progress and existing problems of miRNA in autoimmune myocarditis from its potential mechanism,diagnostic and prognostic biomarkers,and treatment.

关 键 词：微小核糖核酸 自身免疫性心肌炎 发病机制 生物标志物 治疗 

分 类 号：R542.21[医药卫生—心血管疾病]